drugset / Trial / NCT00970632

A Study of Tadalafil in Men With Benign Prostatic Hyperplasia

NCT00970632 ↗

Phase 3 Completed 511 enrolled Eli Lilly and Company
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine whether an experimental drug known as tadalafil given once daily can reduce the symptoms associated with Benign Prostatic Hyperplasia (straining, urinary frequency, feeling like your bladder is still full etc.)

Timeline

Start
2009-10
Primary completion
2011-01
Completion
2011-01

Outcome

Met primary endpoint

paper IPSS significantly improved versus placebo through 12 wk with tadalafil (-2.1; p=0.001; primary efficacy outcome) PMID 22297243 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Tadalafil Small molecule 5 mg Oral
Comparator Tamsulosin Other / unclassified 0.4 mg Oral